MAPT and Alzheimer disease: Notably, the use of okadaic acid to induce tau hyperphosphorylation further corroborated the ability of BT1 to distinguish between physiological and pathological tau, aligning with the expected outcomes for tauopathies such as AD and FTD17,22–24,26,64,66–69.